Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.

被引：0
|
作者：
Sacco, Joseph J.
Harrington, Kevin Joseph
Olsson-Brown, Anna
Chan, Tze Y.
Nenclares, Pablo
Leslie, Isla
Bommareddy, Praveen
Xie, Ben
Wolff, Johannes
Middleton, Mark R.
机构：
[1] Clatterbridge Canc Ctr, Liverpool, Merseyside, England
[2] Univ Liverpool, Liverpool, Merseyside, England
[3] Inst Canc Res, London, England
[4] Replimune Inc, Woburn, MA USA
[5] Univ Oxford, Dept Oncol, Oxford, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9527
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors
    Middleton, M.
    Sacco, Joseph
    Merchan, Jaime
    Thomassen, Amber
    Curti, Brendan
    VanderWalde, Ari
    Olsson-Brown, Anna
    Aroldi, Francesca
    Fotiadis, Nicos
    Baum, Scott
    Kaufman, Howard
    Harrington, Kevin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [22] A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab plus ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial
    Shaw, Heather May
    Patel, Poulam M.
    Payne, Miranda
    Kumar, Satish
    Danson, Sarah
    Highley, Martin
    Prasad, Kellati
    Board, Ruth
    Barlow, Clare
    Larkin, James
    Young, Kate
    Fitzpatrick, Amanda
    Karydis, Ioannis
    Marples, Maria
    Lee, Rebecca
    Corrie, Philippa Gail
    Miller, Robert
    Goodhew, Georgia
    Master, Fayaz
    Durrant, Lindy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab plus ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial
    Shaw, Heather
    Patel, Poulam
    Payne, Miranda
    Kumar, Satish
    Highley, Martin
    Prasad, Kellati
    Board, Ruth
    Barlow, Clare
    Danson, Sarah
    Miller, Robert
    Goodhew, Georgia
    Master, Fayaz
    Durrant, Lindy
    CANCER RESEARCH, 2024, 84 (07)
  • [24] IGNYTE: AN OPEN-LABEL, MULTICENTER, PHASE 1/2 (PH 1/2) CLINICAL TRIAL OF RP1 ± NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Middleton, Mark
    Milhem, Mohammed
    Aroldi, Francesca
    Sacco, Joseph
    VanderWalde, Ari
    Baum, Scott
    Samson, Adel
    Chesney, Jason
    Niu, Jiaxin
    Rhodes, Terence
    Bowles, Tawnya
    Emamekhoo, Hamid
    Tsai, Katy
    In, Gino
    Beasley, Georgia
    Chmielowski, Bartosz
    Dalac-Rat, Sophie
    Kahler, Katharina
    Munoz, Eva
    Olsson-Brown, Anna
    Bommareddy, Praveen
    Menezes, Lavita
    Pirzkall, Andrea
    Coffin, Robert
    Harrington, Kevin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A538 - A538
  • [25] Preliminary results from a FIH, open-label phase 1 study with BMC128, a rationally designed live bacterial consortium, in combination with nivolumab
    Perets, Ruth
    Meshner, Shiri
    Tirosh, Osnat
    Eshar, Shiri
    Metz-Breiner, Alona
    Ben-Shabat, Sheerli Kruger
    Ben-Yehuda, Hila
    Haber, Elran
    Cohen-Asis, Meital
    Maurice-Dror, Corinne
    Ringel, Yehuda
    Holland, Roy
    Shirman, Yelena
    Kutiel, Talia Shentzer
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
    Tolcher, Anthony W.
    LoRusso, Patricia
    Arzt, Jennifer
    Busman, Todd A.
    Lian, Guinan
    Rudersdorf, Niki S.
    Vanderwal, Carol Ann
    Waring, Jeffrey F.
    Yang, Jianning
    Holen, Kyle D.
    Rosen, Lee S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 1041 - 1049
  • [27] Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
    Anthony W. Tolcher
    Patricia LoRusso
    Jennifer Arzt
    Todd A. Busman
    Guinan Lian
    Niki S. Rudersdorf
    Carol Ann Vanderwal
    Jeffrey F. Waring
    Jianning Yang
    Kyle D. Holen
    Lee S. Rosen
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1041 - 1049
  • [28] Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study
    Iyer, Swaminathan P.
    Huen, Auris
    Ai, Weiyun Z.
    Jagadeesh, Deepa
    Lechowicz, Mary J.
    Okada, Craig
    Feldman, Tatyana A.
    Ghione, Paola
    Alderuccio, Juan P.
    Champion, Rebecca
    Kim, Seo-Hyun
    Mohrbacher, Ann
    Routhu, Kasi, V
    Barde, Prajak
    Nair, Ajit M.
    Haverkos, Bradley M.
    HAEMATOLOGICA, 2024, 109 (01) : 209 - 219
  • [29] Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: Results of an open-label multicenter study in Japan
    Ishigooka, J
    Murasaki, M
    Miura, S
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2001, 55 (04) : 353 - 363
  • [30] Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study
    Handunnetti, Sasanka M.
    Khot, Amit
    Anderson, Mary Ann
    Blombery, Piers
    Burbury, Kate
    Ritchie, David
    Hicks, Rodney J.
    Birbirsa, Besiat
    Bressel, Mathias
    Di Iulio, Juliana
    Westerman, David Alan
    Lade, Stephen
    Roberts, Andrew W.
    Seymour, John F.
    Tam, Constantine S.
    BLOOD, 2019, 134
12345